Catriona Yale

CIK 1779308 · Chief Development Officer · last filed 2025-12-09

Catriona Yale is a Chief Development Officer who has filed 52 SEC Form 4 insider transactions across 1 company since 2019. The most recent filing, for AKRO, was dated Dec 9, 2025. Across all open-market trades the lifetime net is −$17.9M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

1

Total Filings

52

Lifetime Open-Market Net

-$17.93M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Akero Therapeutics, Inc. (AKRO) Delisted Chief Development Officer 0 $54.65 $0 -$17.93M 52 2025-12-09

Recent Filings

52 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2025-12-09 Akero Therapeutics, Inc. (AKRO) Delisted Disp (D) −74,800 $0 EDGAR
2025-11-06 Akero Therapeutics, Inc. (AKRO) Delisted Exer (M) +8,266 $200.0K EDGAR
2025-09-12 Akero Therapeutics, Inc. (AKRO) Delisted Sell (S) −659 -$28.4K EDGAR
2025-07-18 Akero Therapeutics, Inc. (AKRO) Delisted Mixed -$330.8K EDGAR
2025-07-02 Akero Therapeutics, Inc. (AKRO) Delisted Grant (A) +890 $21.2K EDGAR
2025-06-20 Akero Therapeutics, Inc. (AKRO) Delisted Mixed -$331.3K EDGAR
2025-06-20 Akero Therapeutics, Inc. (AKRO) Delisted Sell (S) −1,633 -$89.6K EDGAR
2025-06-12 Akero Therapeutics, Inc. (AKRO) Delisted Sell (S) −2,803 -$151.4K EDGAR
2025-05-19 Akero Therapeutics, Inc. (AKRO) Delisted Mixed -$182.0K EDGAR
2025-04-16 Akero Therapeutics, Inc. (AKRO) Delisted Mixed -$152.5K EDGAR
Showing 110 of 52
Page 1 of 6
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.